For patients hospitalized for COVID-19, administration of therapeutic-dose vs prophylactic-dose anticoagulation with heparins ...

Another anticoagulant available for thromboprophylaxis is fondaparinux, an indirect inhibitor of activated factor X. In a double-blind, non-inferiority trial of 2,927 patients undergoing high-risk ...

risks of anticoagulant therapy, and the costs of diagnosis and the treatment of VTE. Data Extraction: I analyzed references cited in reviews and meta-analyses of VTE, and from Medline searches ...

Despite guidelines recommending other anticoagulants for people hospitalized with acute pulmonary embolism (PE), old habits ...

Unfractionated heparin is used for both therapeutic anticoagulation and for maintaining vascular catheter patency via heparin locks and flushes.LMWH is used for therapeutic anticoagulation.

A prospective metanalysis of clinical trials examined the effects of high and low doses of anticoagulation for hospitalized patients with COVID-19. The study found that administering therapeutic ...

Cadrenal Therapeutics (CVKD) recapped its 2024 milestones and highlighted a clear path forward to develop the investigational drug tecarfarin ...

The researchers found that 28-day mortality was reduced with therapeutic-dose versus prophylactic-dose anticoagulation with heparins (odds ratio, 0.77; 95 percent confidence interval, 0.64 to 0.93 ...

Fewer thromboembolic events were seen in association with higher- vs lower-dose anticoagulation, but the risk for major bleeding was greater. (HealthDay News) — For patients hospitalized for ...